IT TAKES AN EXCEPTIONAL TEAM OF DRUG DEVELOPMENT PROFESSIONALS

IT TAKES AN EXCEPTIONAL TEAM OF DRUG DEVELOPMENT PROFESSIONALS

TO FIND A PATH FORWARD WHERE OTHERS MAY FALTER OR STRUGGLE,

TO FIND A PATH FORWARD WHERE OTHERS MAY FALTER OR STRUGGLE,

TO TACKLE THE TOUGHEST OF DISEASES AND INCURABLE CONDITIONS,

TO TACKLE THE TOUGHEST OF DISEASES AND INCURABLE CONDITIONS,

TO SEEK NOVEL APPROACHES. BECAUSE LIVES ARE DEPENDING ON IT.

TO SEEK NOVEL APPROACHES. BECAUSE LIVES ARE DEPENDING ON IT.

The Team

Sven Jacobson

Sven Jacobson

CEO
Sven has over three decades of senior management experience. He is the Managing Partner of Embark Healthcare. He received his Bachelor of Science Engineering (BSc Eng) and MBA degrees from the University of the Witwatersrand in Johannesburg, South Africa. Sven has co-founded several pharmaceutical companies.
David Geliebter

David Geliebter

Executive Chairman
David has over 50 years of experience successfully starting and growing businesses. David is the Managing Partner of Embark Healthcare (formerly Carrot Capital). He is a past winner of the Ernst & Young Entrepreneur of the Year Award. David has been involved in the creation of several pharmaceutical companies.
Thomas W. MacAllister, PhD, JD

Thomas W. MacAllister, PhD, JD

General Counsel and VP of Research & Development
Thomas is a licensed IP attorney and a pharmaceutical executive with a PhD in molecular biology. He has over 30 years of experience in the pharmaceutical industry.
Ann C. Tunstall, PhD

Ann C. Tunstall, PhD

VP of Regulatory and Clinical Operations
Ann Tunstall, PhD, has worked as a regulatory and clinical professional in the healthcare industry for more than 25 years. She has a PhD in Biomedical Engineering from the University of Texas Southwestern Medical Center, an MS in Material Science, and a BS in Biomedical Engineering from Duke University.
Roland Gerritsen Van Der Hoop, MD

Roland Gerritsen Van Der Hoop, MD

Chief Medical Officer
Roland is a pharmaceutical executive with over 30 years of experience. He has an MD and PhD from Utrecht University, the Netherlands. He has been involved in dozen of clinical trials.
Ibrahim Mian, MD

Ibrahim Mian, MD

Medical Director and Director of Operations
Ibrahim brings a decade of clinical experience in family medicine. With almost half a decade of involvement in the industry, he is quickly proving himself as a skilled pharmaceutical physician. He has an MD from Wake Forest University School of Medicine and a BS in Biology from Duke University.
Oscar Liu, PhD

Oscar Liu, PhD

Manager of CMC
Oscar has been working in the pharmaceutical industry for over 20 years with increasing responsibilities. Oscar has led CMC development for multiple NDA and ANDA approvals. He has a Ph.D from Duke University, M.S. from SUNY-Binghamton, and B.S. from Xiamen University.

Sabrina Williams

Director of Clinical and Regulatory Affairs
Sabrina has almost 20 years of drug development experience. She received her BS in Pharmaceuticals Science at the Massachusetts College of Pharmacy and Allied Health.
Amy Kreit

Amy Kreit

Finance Manager
Amy has over 30 years of diverse accounting experience from startups to Fortune 500 companies. She has a BS in Accounting from Syracuse University.
Enda Anatole

Enda Anatole

Office Assistant
Enda holds a BA in Human Resource Management from the Zicklin School of Business at Baruch College.

Scientific Advisors

Michael Benatar

Michael Benatar, MD, PhD

Professor of Neurology - University of Miami, Scientific Advisor to Woolsey
Michael is a Walter Bradley Chair in ALS Research and the Executive Director of the University of Miami ALS Center. He is also Chief of the Neuromuscular Division and Vice Chair of Clinical & Translational Research in the Department of Neurology. Dr. Benatar is renowned for both his clinical and biomarker expertise in ALS.
Ruben van Eijk

Ruben van Eijk, MD, PhD

Assistant Professor and Medical Statistician - University Medical Center Utrecht,
Scientific Advisor to Woolsey
Ruben’s research focuses on the development of innovative clinical trial methodologies for ALS and is a highly-sought-after statistician in ALS development programs.

Paul Lingor, MD

Professor of Neurology - University Medicine Göttingen, Scientific Advisor to Woolsey
Paul’s research group focuses on models of neurotrauma and neurodegeneration. He is the Principal Investigator for the ROCK-ALS study, a European-based, multicenter, double-blind, randomized, placebo controlled 120-patient phase 2a trial of intravenous (IV) fasudil (the active ingredient in BRAVYL) in ALS patients.

Outside Board and Board Advisors

David Epstein

David Epstein

Board Advisor
David has over three decades of pharmaceutical experience, having previously served as CEO of Novartis Pharmaceuticals (2010- 2016), and most recently heading Seagen as Chief Executive Officer (2022-), guiding the company through its acquisition by Pfizer. David holds a BS Degree in Pharmacy from Rutgers University College of Pharmacy, and an MBA from the Columbia University Graduate School of Business.
Natalie Langner

Nataly Langner

Board Observer
Nataly is actively involved in managing investments of the Langner Family, in addition to her many philanthropic activities, which include supporting multiple charities internationally, and acting as Chair of the Advisory Board for Dr. E. A. Langner Stiftung (family non-profit foundation).
Rich Nelson

Rich Nelson

Outside Board Observer
Rich began his career as a mergers and acquisitions and corporate finance attorney at Skadden Arps. Rich is the Managing Director of M&A for IAC, home to dozens of popular online brands and services used by millions of consumers each day. He previously served as General Counsel and SVP of Corporate Development at RSL COM USA, Inc., a telecommunications company founded by Ronald Lauder.

Claude Piché, DVM, MSc

Outside Board Member
Claude has over 25 years of experience in developing and commercializing pharmaceuticals in the industry. As co-founder of Locemia Solutions, he led the creation and development of Baqsimi, the first and only dry nasal spray to treat low blood sugar emergencies. The company was sold to Eli Lilly. Claude holds degrees from the University of Saskatchewan (DVM) and the University of Calgary (MSc).